US Retail Drug Spending Growth Slowing With No New Sovaldis In Sight

Rate of growth in prescription drug spending is expected to average 6.7% per year from 2016 through 2025, National Health Expenditures report from CMS projects.

RollOfDollarswithPills_1200x675

Retail prescription drug spending is expected to grow an average of less than 7% per year for the 10-year period 2016 through 2025, according to the annual National Health Expenditure Projections released by the Centers for Medicare and Medicaid Services Office of the Actuary July 14.

Growth in spending will slow to 6.3% in 2016, “as the influence on spending from newly approved drugs is expected...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By 

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Diversity Action Plans: What To Submit And When

 
• By 

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

Stealth’s Elamipretide: Efficacy In Barth Syndrome Not Shown, US FDA Says

 
• By 

Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.

New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.

More from North America

Stealth’s Elamipretide: Efficacy In Barth Syndrome Not Shown, US FDA Says

 
• By 

Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.

New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By 

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.